Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Pharmaceuticals presented long-term data from its Phase 2 BESTOW trial showing tegoprubart-treated patients maintained higher kidney function compared to tacrolimus. At 18 months, the tegoprubart arm demonstrated a statistically significant 12 mL/min/1.73 m² advantage in mean eGFR (74 vs. 61) and reported no biopsy-proven acute rejection events after six months.
Key figures
- Drug Name
- tegoprubart
- Phase Of Trial
- Phase 2
- Egfr advantage 18mo
- 12 mL/min/1.73 m²
- Egfr tacrolimus 18mo
- 61 mL/min/1.73 m²
- Egfr tegoprubart 18mo
- 74 mL/min/1.73 m²
- Bpar events tacrolimus total
- 7
- Bpar events tegoprubart post 6mo
- 0
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.